Chi-Jung Huang

Chi-Jung Huang

Auto-generated profile, based on publicly available information

Chi-Jung Huang

Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
YTYi‐Ching Tsai
Yi‐Ching Tsai
YTYen‐Po Tsao
Yen‐Po Tsao
CHChi‐Jung Huang
Chi‐Jung Huang
YTYen‐Hsuan Tai
Yen‐Hsuan Tai
YSYang‐Chin Su
Yang‐Chin Su
HCHao-Min Cheng
Hao-Min Cheng
Hypertension‐related death is the leading cause of mortality worldwide, making blood pressure (BP) control an important issue. Salt substitute is a non‐pharmaceutical strategy to improve hypertension control. The goal of this study was to evaluate the effect of salt substitute on BP and cardiovascular disease. The authors searched the Cochrane Library and PubMed databases through March 2022, and assessed the risk‐of‐bias for included studies by the Cochrane risk‐of‐bias tool. Twenty‐three randomized controlled trials with 32073 patients were included in our systematic review. A meta‐analysis with random effects was performed to analyze the effects of salt substitute on systolic and diastolic BP, 24‐h urinary sodium and potassium, and cardiovascular and all‐cause mortality. In the random‐effects model, participants consuming salt substitute showed significant reduction in systolic BP (mean difference (MD) −4.80 mmHg, 95% confidence interval (CI) −6.12 to −3.48, P < 0.0001) and diastolic BP (MD −1.48 mmHg, 95% CI −2.06 to −0.90, P < 0.0001) compared with participants consuming normal salt. In the urine electrolyte analysis, the salt substitute group had significant reduction in 24‐h urine sodium (MD −22.96 mmol/24‐h, P = 0.0001) and significant elevation in 24‐h urine potassium (MD 14.41 mmol/24‐h, P < 0.0001). Of the five studies with mortality outcome data, salt substitute significantly reduced all‐cause mortality (hazard ratio 0.88, P = 0.0003). In conclusion, our analyses showed that salt substitute has a strong effect on lowering BP and reducing all‐cause mortality. By modifying the daily diet with salt substitute, the authors can improve BP control by using this non‐pharmaceutical management.

16 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
WCWei‐Lun Chang
Wei‐Lun Chang
YCYing‐Fan Chen
Ying‐Fan Chen
YLYu‐Hsuan Lee
Yu‐Hsuan Lee
MSMing‐Neng Shiu
Ming‐Neng Shiu
PCPo‐Yin Chang
Po‐Yin Chang
HCHao-Min Cheng
Hao-Min Cheng
Background: The prognosis of high or markedly low diastolic blood pressure (DBP) with normalized on‐treatment systolic blood pressure on major adverse cardiovascular events (MACEs) is uncertain. This study examined whether treated isolated diastolic hypertension (IDH) and treated isolated low DBP (ILDBP) were associated with MACEs in patients with hypertension. Methods and Results: A total of 7582 patients with on‐treatment systolic blood pressure <130 mm Hg from SPRINT (Systolic Blood Pressure Intervention Trial) were categorized on the basis of average DBP: 0.05). Conclusions: In this secondary analysis of SPRINT, among treated patients with normalized systolic blood pressure, excessively low DBP was associated with an increased MACE risk, while treated IDH was not. Further research is required for treated ILDBP management.

15 February 2024 in Physical and Engineering Sciences in Medicine
Verified
Journal Article
Open access
PDF file
CHChieh-Chun Huang
Chieh-Chun Huang
SSShih-Hsien Sung
Shih-Hsien Sung
WWWei-Ting Wang
Wei-Ting Wang
YSYin-Yuan Su
Yin-Yuan Su
CHChi-Jung Huang
Chi-Jung Huang
HCHao-Min Cheng
Hao-Min Cheng
Hemodynamic parameters derived from pulse wave analysis have been shown to predict long-term outcomes in patients with heart failure (HF). Here we aimed to develop a deep-learning based algorithm that incorporates pressure waveforms for the identification and risk stratification of patients with HF. The first study, with a case–control study design to address data imbalance issue, included 431 subjects with HF exhibiting typical symptoms and 1545 control participants with no history of HF (non-HF). Carotid pressure waveforms were obtained from all the participants using applanation tonometry. The HF score, representing the probability of HF, was derived from a one-dimensional deep neural network (DNN) model trained with characteristics of the normalized carotid pressure waveform. In the second study of HF patients, we constructed a Cox regression model with 83 candidate clinical variables along with the HF score to predict the risk of all-cause mortality along with rehospitalization. To identify subjects using the HF score, the sensitivity, specificity, accuracy, F1 score, and area under receiver operating characteristic curve were 0.867, 0.851, 0.874, 0.878, and 0.93, respectively, from the hold-out cross-validation of the DNN, which was better than other machine learning models, including logistic regression, support vector machine, and random forest. With a median follow-up of 5.8 years, the multivariable Cox model using the HF score and other clinical variables outperformed the other HF risk prediction models with concordance index of 0.71, in which only the HF score and five clinical variables were independent significant predictors (p < 0.05), including age, history of percutaneous coronary intervention, concentration of sodium in the emergency room, N-terminal pro-brain natriuretic peptide, and hemoglobin. Our study demonstrated the diagnostic and prognostic utility of arterial waveforms in subjects with HF using a DNN model. Pulse wave contains valuable information that can benefit the clinical care of patients with HF.

1 December 2025 in IEEE Open Journal of Ultrasonics, Ferroelectrics, and Frequency Control
Verified
Journal Article
Open access
CLChing-Yao Lu
Ching-Yao Lu
SLShao-Kai Lu
Shao-Kai Lu
HCHsiang-Chung Cheng
Hsiang-Chung Cheng
YCYun-Chieh Chou
Yun-Chieh Chou
JWJiun-Jr Wang
Jiun-Jr Wang
GJGeng-Shi Jeng
Geng-Shi Jeng
The simultaneous measurement of blood pressure (P) and volume flow rate (Q) is essential for a comprehensive hemodynamic assessment, yet it remains a significant technical challenge. This work presents a novel ultrasound-based system that enables the simultaneous estimation of high-resolution P and Q waveforms at the same vascular location using a single transducer. We propose a system that leverages ultrafast multi-angle plane wave imaging to acquire high-frame-rate B-mode image sequences. A machine learning optical flow model called RAFT was adapted and fine-tuned for ultrasound to perform robust vector flow imaging for Q quantification. Concurrently, an efficient 2-D speckle tracking algorithm tracks vessel wall motion to derive the diameter waveform, from which P is estimated using a calibrated exponential model. The method was evaluated in flow phantom experiments and in vivo on the carotid arteries of healthy subjects. In phantom studies, the proposed method demonstrated high accuracy, with pressure estimates achieving a root-mean-square error of 1.76 mmHg against reference sensors. Crucially, Q estimates showed improved accuracy compared to conventional color Doppler and existing vector flow imaging methods such as blood speckle tracking and multi-angle vector Doppler. In vivo results confirmed that the proposed method provides high-resolution P and Q waveforms, enabling the reliable calculation of hemodynamic energy parameters sensitive to vascular aging. This work introduces a fully ML-driven ultrasound velocimetry method integrated with blood pressure estimation from vessel wall motion, potentially enhancing the diagnosis of cardiovascular and cerebrovascular diseases.

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SCSzu-Han Chen
Szu-Han Chen
YLYu‐Hsuan Lee
Yu‐Hsuan Lee
SCShao-Yuan Chuang
Shao-Yuan Chuang
MFMarat Fudim
Marat Fudim
CLChun-Wei Lee
Chun-Wei Lee
HCHao-Min Cheng
Hao-Min Cheng
Background: Obesity and systemic inflammation have each been independently associated with an increased risk of heart failure (HF). However, whether inflammatory pathways mediate the association between obesity and the development of heart failure remains unclear. Methods: We analyzed data from a community‐based cohort of 1998 participants to evaluate multiple adiposity indicators in relation to incident HF. hs‐CRP (high‐sensitivity C‐reactive protein) was examined as a mediator using causal mediation analysis to quantify the contribution of systemic inflammation. Kaplan–Meier analyses and multivariable Weibull accelerated failure time models were applied to estimate hazard ratios (HRs) for HF occurrence. Results: Over a median follow‐up of 6.9 years, individuals with elevated hs‐CRP levels showed significantly lower HF‐free survival (log‐rank P =0.010). In multivariable accelerated failure time models, indicators of central obesity and hs‐CRP—but not BMI—were significantly associated with higher HF risk (eg, waist circumference: HR=1.30 [95% CI: 1.05–1.61], P =0.017; hs‐CRP: HR=1.25 [1.05–1.51], P =0.013). Mediation analysis revealed that hs‐CRP accounted for 26.5% of the effect of waist circumference and 32.4% of the effect of waist‐to‐height ratio on HF risk, with statistically significant indirect effects for both. Conclusions: Our findings build upon recent conceptual advances by demonstrating that central obesity contributes to HF largely through inflammation. By quantifying the proportion of HF risk attributable to systemic inflammation, this study reinforces the rationale for prioritizing both anti‐obesity and anti‐inflammatory strategies in HF prevention.

1 September 2026 in Hypertension
Verified
Journal Article
Closed access
SCSzu-Han Chen
Szu-Han Chen
CYChih-Yu Yeh
Chih-Yu Yeh
YCYu-Pan Chiang-Lin
Yu-Pan Chiang-Lin
CHChi-Jung Huang
Chi-Jung Huang
SCShao-Yuan Chuang
Shao-Yuan Chuang
HCHao-Min Cheng
Hao-Min Cheng
BACKGROUND: Hypertension guidelines generally recommend uniform sodium restriction although determinants of salt sensitivity, or sodium-blood pressure responsiveness, remain incompletely quantified. We estimated the population sodium-blood pressure dose-response, identified clinical modifiers, quantified high salt sensitivity prevalence, and derived the number needed to restrict sodium intake to prevent 1 cardiovascular event across clinical strata. METHODS: PubMed, Excerpta Medica Database, and Cochrane were searched from inception to April 2025 for sodium intervention trials and observational studies. Blood pressure response was standardized per 50-mmol/d sodium difference. Random-effects meta-regression evaluated clinical modifiers. A highly salt-sensitive phenotype was defined a priori as a systolic blood pressure (SBP) decrease ≥3 mm Hg per 50-mmol/d reduction. RESULTS: We included 160 studies (255 estimates; n=16 443). Each 50-mmol/d higher urinary sodium excretion was associated with 1.76-mm Hg higher SBP (95% CI, 1.54–1.98). Age and baseline SBP were the strongest modifiers (0.41 mm Hg per 5 years; 0.23 mm Hg per 5 mm Hg). Salt-sensitive phenotype prevalence rose from 12.5% (age <40 years) to 56.5% (≥60 years) and from 16.3% (SBP <120 mm Hg) to 54.1% (≥130 mm Hg). Under a policy-relevant 100-mmol/d sodium reduction, number needed to restrict ranged from ≈1334 in younger, normotensive, lean individuals (age <60 years, SBP <130 mm Hg, and body mass index <25 kg/m 2 ) to ≈87 in older adults with hypertension and elevated body mass index (age ≥60 years, SBP ≥130 mm Hg, and body mass index ≥25 kg/m 2 ), a 15-fold gradient. CONCLUSIONS: Salt sensitivity varied across age, SBP, and body mass index strata. These findings suggest that routinely measured clinical characteristics may help identify populations with greater expected blood pressure response to sodium reduction.